Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Barnaby Pickering

Senior Writer

London, UK

Barnaby lives and works in Yorkshire. Having graduated from University College London with a master's degree in biomedical engineering in 2020, Barnaby is passionate about cutting-edge medical technology. Key areas of focus for Barnaby include diabetes, nanotechnology, machine learning and artificial intelligence.

Latest From Barnaby Pickering

Execs On The Move: New Leaders for Vyaire, Nevro, And More In May 2023

An interactive summary of recent executive-level company changes and promotions in the medical device and diagnostics sectors.

Executive Changes Medical Device

Minute Insight: Owlstone Medical’s 'Breath Biopsy' Tech Adopted By US Military

The company will create a handheld version of its FAIMS technology, to be used in rapid testing for transmissible illnesses in combat scenarios.

Minute Insights Respiratory

Illumina Appeals FTC Decision, Grail Swings And Misses

Illumina has formally appealed the FTC’s decision to block its acquisition of Grail, just days after Grail mistakenly sent letters to patients suggesting they could have cancer.

Clinical Trials Diagnostics

Exec Chat: PacBio Addresses Latest Results, New Tech And Long-Read Sequencing’s Future

PacBio has been burning through investors’ cash as it works to make long-read sequencing more accessible. Neil Ward, the company’s general manager, laid out his thoughts on the technology, its place in the market and how genomics data can be both effectively and fairly utilized.

Rare Diseases Platform Technologies

Investor Eye: A Licensing-Based Approach May Be Best For Revolutionary IP

Keeping a firm grip on one’s IP is a cornerstone of most innovative businesses. However, Robert Cote, CEO of Cote Capital, believes that if the idea is good enough to keep close, it’s good enough to license out.

Investor Eye Strategy

The Illumina Shareholder Votes Are In, And Nobody Got What They Wanted

Carl Icahn was successful in ousting Illumina’s chair, however its CEO, Francis deSouza remains. Both analysts and investors believe this could further encourage Illumina to divest Grail.

Medical Device Commercial
See All
UsernamePublicRestriction

Register